Cite
Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.
MLA
Liontos, M., et al. “Neutrophil-to-Lymphocyte Ratio and Chemotherapy Response Score as Prognostic Markers in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy.” Journal of Ovarian Research, vol. 14, no. 1, Nov. 2021, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s13048-021-00902-0.
APA
Liontos, M., Andrikopoulou, A., Koutsoukos, K., Markellos, C., Skafida, E., Fiste, O., Kaparelou, M., Thomakos, N., Haidopoulos, D., Rodolakis, A., Dimopoulos, M. A., & Zagouri, F. (2021). Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. Journal of Ovarian Research, 14(1), 1–10. https://doi.org/10.1186/s13048-021-00902-0
Chicago
Liontos, M., A. Andrikopoulou, K. Koutsoukos, C. Markellos, E. Skafida, O. Fiste, M. Kaparelou, et al. 2021. “Neutrophil-to-Lymphocyte Ratio and Chemotherapy Response Score as Prognostic Markers in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy.” Journal of Ovarian Research 14 (1): 1–10. doi:10.1186/s13048-021-00902-0.